Spotlight on the new ACC/AHA lipid and JNC8 hypertension guidelines, EGFR inhibitors vs chemotherapy for NSCLC, and more.

JAMA Editor’s Summary

Spotlight on the new ACC/AHA lipid and JNC8 hypertension guidelines, EGFR inhibitors vs chemotherapy for NSCLC, and more.

Editor's Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the April 09, 2014 issue

April 8, 2014

Listen on your favorite player Take me to this show’s page

Newer →

Safety of balloon- vs self-expandable TAVR valves, effects of aleglitazar and metformin after ACS in patients with DM, management of fibromyalgia, and more.

← Older

JAMA: 2014-04-01, Vol. 311, No. 13, Editor's Audio Summary

Facebook Twitter Buffer LinkedIn WhatsApp

Spotlight on the new ACC/AHA lipid and JNC8 hypertension guidelines, EGFR inhibitors vs chemotherapy for NSCLC, and more.

Editor’s Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the April 09, 2014 issue

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

00:00

00:00